 |
市場調查報告書
商品編碼
1572513
靜脈鐵劑市場、機會、成長動力、產業趨勢分析與預測，2024-2032Intravenous Iron Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032 |
||||||
2023 年，全球靜脈 (IV) 鐵劑藥物市場估值約為 17 億美元，預計 2024 年至 2032 年複合年成長率為 6.7%。治療或預防不能有效吸收口服鐵補充劑或需要快速補充鐵的患者的缺鐵性貧血。
慢性腎臟病（CKD）、癌症和發炎性疾病等慢性病的盛行率不斷上升推動了市場的成長。這些健康問題通常會導致貧血，增加了對靜脈鐵劑療法的需求，以恢復鐵水平並改善患者的預後。促進市場擴張的其他因素包括缺鐵診斷意識的提高、人口老化以及靜脈注射鐵劑藥物配方的不斷進步。
整個靜脈注射 (IV) 鐵劑藥物行業根據藥物類型、應用、配銷通路和地區進行分類。
IV鐵藥物市場按藥物類型細分，包括右旋糖酐鐵、蔗糖鐵和羧基麥芽糖鐵。其中，羧基麥芽糖鐵部分預計到2032 年將達到15 億美元。的首選患者和醫療保健提供者。
從應用來看，市場分為CKD、發炎性腸道疾病和癌症等細分市場。 CKD 細分市場到 2023 年將達到 10 億美元，預計將繼續佔據主導地位。 CKD 患者經常難以胃腸道吸收鐵，這使得靜脈鐵劑成為更有效的治療選擇。此外，靜脈注射鐵有助於提高血紅蛋白水平並刺激紅血球生成，這對於控制 CKD 患者的貧血至關重要。
靜脈配銷通路的通路分為醫院藥局、零售藥局和網路藥局。醫院藥局部門預計到 2032 年將達到 14 億美元，受益於其在靜脈注射療法管理、副作用監測和確保藥物製劑嚴格品質控制方面的專業知識。
美國市場預計將大幅成長，到 2032 年將達到 10 億美元。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 慢性病盛行率上升
- 提高及時診斷鐵缺乏症的意識
- 老年人口不斷增加
- 靜脈注射鐵劑藥物配方的進展
- 產業陷阱與挑戰
- 靜脈注射補鐵藥物相關的高成本
- 不良反應和安全問題
- 成長動力
- 成長潛力分析
- 監管環境
- 管道分析
- 2023 年定價分析
- 按地區
- 按關鍵人物
- 未來市場趨勢
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 公司矩陣分析
- 主要市場參與者的競爭分析
- 競爭定位矩陣
- 戰略儀表板
第 5 章：市場估計與預測：按藥物類型，2021 - 2032 年
- 主要趨勢
- 右旋糖酐鐵
- 蔗糖鐵
- 羧基麥芽糖鐵
- 其他藥物類型
第 6 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 慢性腎臟病
- 發炎性腸道疾病
- 癌症
- 其他應用
第 7 章：市場估計與預測：按配銷通路，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥房
- 網路藥房
第 8 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
- 亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 9 章：公司簡介
- AbbVie Inc.
- AdvaCare Pharma
- Akebia Therapeutics, Inc.
- AMAG Pharmaceuticals. Inc.
- Bayer AG
- Covis Pharma GmbH
- CSL Limited
- Daiichi Sankyo Company, Ltd.
- F. Hoffmann-La Roche Ltd.
- Fresenius SE and Co. KGaA
- Novartis AG
- PHARMACOSMOS A/S
- Rockwell Medical, Inc.
- Sanofi
- Zydus Lifesciences Limited
The Global Intravenous (IV) Iron Drugs Market was valued at approximately USD 1.7 billion in 2023 and is expected to grow at a CAGR of 6.7% from 2024 to 2032. IV iron drugs are specialized formulations of iron administered directly into the bloodstream, commonly used for treating or preventing iron deficiency anemia in patients who cannot effectively absorb oral iron supplements or require rapid iron replenishment.
The market growth is driven by the increasing prevalence of chronic conditions such as chronic kidney disease (CKD), cancer, and inflammatory disorders. These health issues often result in anemia, heightening the need for IV iron therapies to restore iron levels and improve patient outcomes. Additional factors contributing to market expansion include rising awareness of iron deficiency diagnosis, an aging population, and ongoing advancements in IV iron drug formulations.
The overall intravenous (IV) iron drugs industry is segregated based on Drug Type, Application, Distribution Channel, and Region.
The IV iron drugs market is segmented by drug type, including iron dextran, iron sucrose, and ferric carboxymaltose. Among these, the ferric carboxymaltose segment is projected to reach USD 1.5 billion by 2032. This drug offers several benefits, such as high elemental iron concentration, fewer infusions, quicker administration times, and a favorable safety profile, making it a preferred choice for many patients and healthcare providers.
In terms of application, the market is divided into segments like CKD, inflammatory bowel disease, and cancer. The CKD segment accounted for USD 1 billion in 2023 and is expected to remain dominant. CKD patients often struggle with gastrointestinal absorption of iron, making IV iron a more efficient treatment option. Additionally, IV iron helps to increase hemoglobin levels and stimulate red blood cell production, which is crucial for managing anemia in CKD patients.
The distribution channel for IV iron drugs is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment is projected to reach USD 1.4 billion by 2032, benefiting from their expertise in administering IV therapies, monitoring for side effects, and ensuring stringent quality control in drug preparation.
The U.S. market is expected to grow significantly, reaching USD 1 billion by 2032. Factors such as a robust healthcare infrastructure and the rising prevalence of chronic conditions contribute to the increasing demand for IV iron drugs in the country.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of chronic diseases
- 3.2.1.2 Increasing awareness towards timely diagnosis of iron deficiencies
- 3.2.1.3 Growing geriatric population
- 3.2.1.4 Advancements in intravenous iron drug formulations
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost associated with intravenous iron drugs
- 3.2.2.2 Adverse reactions and safety concerns
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Pipeline analysis
- 3.6 Pricing analysis, 2023
- 3.6.1 By region
- 3.6.2 By key player
- 3.7 Future market trends
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Iron dextran
- 5.3 Iron sucrose
- 5.4 Ferric carboxymaltose
- 5.5 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Chronic kidney disease
- 6.3 Inflammatory bowel disease
- 6.4 Cancer
- 6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Hospital pharmacy
- 7.3 Retail pharmacy
- 7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
- 9.1 AbbVie Inc.
- 9.2 AdvaCare Pharma
- 9.3 Akebia Therapeutics, Inc.
- 9.4 AMAG Pharmaceuticals. Inc.
- 9.5 Bayer AG
- 9.6 Covis Pharma GmbH
- 9.7 CSL Limited
- 9.8 Daiichi Sankyo Company, Ltd.
- 9.9 F. Hoffmann-La Roche Ltd.
- 9.10 Fresenius SE and Co. KGaA
- 9.11 Novartis AG
- 9.12 PHARMACOSMOS A/S
- 9.13 Rockwell Medical, Inc.
- 9.14 Sanofi
- 9.15 Zydus Lifesciences Limited
